PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Recs

0
Player Avatar judged222 (75.14) Submitted: 6/6/2011 1:16:11 PM : Outperform Start Price: $5.66 PDLI Score: +12.79

MF

Featured Broker Partners


Advertisement